Celldex Therapeutics, INC Form 4 insider transactions

Celldex Therapeutics' SVP and Chief Medical Officer, Diane C. Young, was granted 72,000 incentive stock options as part of the company's 2021 Omnibus Equity Incentive Plan.

Celldex Therapeutics, Inc. (CLDX) Executive VP & CSO Tibor Keler was granted 93,000 incentive stock options with an exercise price of $19.53, vesting over four years.

Celldex Therapeutics, Inc. President and CEO, Anthony S. Marucci, was granted 300,000 incentive stock options with an exercise price of $19.53, vesting over four years.

Celldex Therapeutics, Inc. director Denice Torres was granted 33,000 non-qualified stock options with an exercise price of $19.53, vesting in three equal annual installments starting June 5, 2026.

Celldex Therapeutics Director Rita Jain was granted 16,500 non-qualified stock options with an exercise price of $19.53, aligning her interests with shareholder value.

Celldex Therapeutics, Inc. Director Garry Arthur Neil was granted 16,500 non-qualified stock options with an exercise price of $19.53 per share, aligning his interests with shareholder value.

Celldex Therapeutics, Inc. Director Harry Penner Jr. was granted 16,500 non-qualified stock options with an exercise price of $19.53, exercisable from June 5, 2026, and expiring on June 5, 2035.

Celldex Therapeutics Director Herbert J. Conrad was granted 16,500 non-qualified stock options with an exercise price of $19.53, exercisable from June 5, 2026, and expiring on June 5, 2035.

Celldex Therapeutics, Inc. (CLDX) director James J. Marino was granted 16,500 non-qualified stock options with an exercise price of $19.53, exercisable from June 5, 2026, and expiring in 2035.

Celldex Therapeutics, Inc. (CLDX) director Keith L. Brownlie was granted 16,500 non-qualified stock options with an exercise price of $19.53 per share, as reported in a recent SEC Form 4 filing.

Celldex Therapeutics, Inc. director Cheryl Cohen was granted 16,500 non-qualified stock options with an exercise price of $19.53, exercisable from June 5, 2026, and expiring on June 5, 2035.

Director James J. Marino of Celldex Therapeutics transferred 10,500 shares of common stock as a gift to a family member.

Celldex Therapeutics CEO Anthony Marucci recently purchased 11,500 shares of the company's common stock at a price of $26.82 per share.

Martin Samuel Bates, SVP and CFO of Celldex Therapeutics, reports the exercise of stock options and subsequent sale of shares on June 14, 2024.

Elizabeth Crowley, SR. VP & CPDO of Celldex Therapeutics, exercised stock options and sold shares on June 14, 2024.

Freddy A. Jimenez, SVP & General Counsel of Celldex Therapeutics, acquired 75,000 incentive stock options on June 13, 2024, according to a Form 4 filing with the SEC.

Diane C. Young, SVP, Chief Medical Officer of Celldex Therapeutics, reports the acquisition of incentive stock options.

Margo Heath-Chiozzi, SVP of Regulatory Affairs at Celldex Therapeutics, was granted incentive stock options to purchase 82,000 shares of common stock.

Sarah Cavanaugh, SVP of Corporate Affairs & Administration at Celldex Therapeutics, acquired 78,000 incentive stock options on June 13, 2024, according to a Form 4 filing.

Elizabeth Crowley, SR. VP & CPDO of Celldex Therapeutics, acquired 85,000 incentive stock options on June 13, 2024, according to a Form 4 filing.

Richard M. Wright, SR. VP & CCO of Celldex Therapeutics, acquired 65,000 incentive stock options on June 13, 2024, according to a Form 4 filing with the SEC.

Ronald Pepin, Senior VP & CBO of Celldex Therapeutics, acquired 20,000 incentive stock options on June 13, 2024, according to a Form 4 filing.

Samuel Bates Martin, SVP and CFO of Celldex Therapeutics, acquired 81,000 incentive stock options on June 13, 2024, according to a Form 4 filing with the SEC.

Tibor Keler, Executive VP & CSO of Celldex Therapeutics, reports the acquisition of 93,000 incentive stock options.

Celldex Therapeutics CEO Anthony S. Marucci was granted 300,000 incentive stock options on June 13, 2024, according to a Form 4 filing with the SEC.

Director Rita Jain acquired 16,500 non-qualified stock options in Celldex Therapeutics on June 13, 2024.

Director Garry A. Neil reports acquisition of 16,500 non-qualified stock options in Celldex Therapeutics.

Cheryl Cohen, a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options on June 13, 2024, under the company's 2021 Omnibus Equity Incentive Plan.

Keith L. Brownlie, a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options on June 13, 2024, according to a Form 4 filing with the SEC.

James J. Marino, a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options on June 13, 2024, under the company's 2021 Omnibus Equity Incentive Plan.